Imfinzi® (durvalumab) – New indication
March 30, 2020 - AstraZeneca announced the FDA approval of Imfinzi (durvalumab), in combination with etoposide and either carboplatin or cisplatin, for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).
Download PDF
